Literature DB >> 28138869

Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence.

Tatsuya Yoshida1, Hiromi Furuta2, Toyoaki Hida2.   

Abstract

Nivolumab offers a statistically superior survival benefit over docetaxel in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer (NSCLC). However, we unexpectedly encountered "tumor flare" that was associated with initially increased tumor lesion size and subsequently decreased tumor burden in patients with NSCLC treated with nivolumab, which is known as pseudoprogression. Tumor flare with rapid progression related to accelerated progression after nivolumab treatment has also been observed. Here we report two patients having early irradiated field recurrence who experienced "tumor flare" that showed pseudoprogression and rapid progression. In addition, we present a brief literature review on "tumor flare" after nivolumab treatment.

Entities:  

Keywords:  Nivolumab; Non-small cell lung cancer; Pseudoprogression; Tumor flare

Mesh：

Substances：

Year:  2017        PMID： 28138869     DOI： 10.1007/s12032-017-0895-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  11 in total

1.  Pseudoprogression and Immune-Related Response in Solid Tumors.

Authors:  Victoria L Chiou; Mauricio Burotto
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

Review 2.  Role of Local Radiation Therapy in Cancer Immunotherapy.

Authors:  Sandra Demaria; Encouse B Golden; Silvia C Formenti
Journal:  JAMA Oncol       Date:  2015-12       Impact factor: 31.777

3.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Authors:  Stéphane Champiat; Laurent Dercle; Samy Ammari; Christophe Massard; Antoine Hollebecque; Sophie Postel-Vinay; Nathalie Chaput; Alexander Eggermont; Aurélien Marabelle; Jean-Charles Soria; Charles Ferté
Journal:  Clin Cancer Res       Date:  2016-11-08       Impact factor: 12.531

4.  Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases.

Authors:  O Kanai; K Fujita; M Okamura; K Nakatani; T Mio
Journal:  Ann Oncol       Date:  2016-03-31       Impact factor: 32.976

5.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.

Authors:  Claire Vanpouille-Box; Julie M Diamond; Karsten A Pilones; Jiri Zavadil; James S Babb; Silvia C Formenti; Mary Helen Barcellos-Hoff; Sandra Demaria
Journal:  Cancer Res       Date:  2015-04-09       Impact factor: 12.701

6.  Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.

Authors:  Sonja Kleffel; Christian Posch; Steven R Barthel; Hansgeorg Mueller; Christoph Schlapbach; Emmanuella Guenova; Christopher P Elco; Nayoung Lee; Vikram R Juneja; Qian Zhan; Christine G Lian; Rahel Thomi; Wolfram Hoetzenecker; Antonio Cozzio; Reinhard Dummer; Martin C Mihm; Keith T Flaherty; Markus H Frank; George F Murphy; Arlene H Sharpe; Thomas S Kupper; Tobias Schatton
Journal:  Cell       Date:  2015-09-10       Impact factor: 41.582

7.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors:  Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

8.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  Transforming growth factor-beta activation in irradiated murine mammary gland.

Authors:  M H Barcellos-Hoff; R Derynck; M L Tsang; J A Weatherbee
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808
View more
  7 in total

Review 1.  Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature.

Authors:  Chao Liu; Jingjing Piao; Zhiyang Shang
Journal:  BMC Urol       Date:  2021-03-21       Impact factor: 2.264

2.  Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency.

Authors:  Anirban Das; Sumedha Sudhaman; Daniel Morgenstern; Ailish Coblentz; Jiil Chung; Simone C Stone; Noor Alsafwani; Zhihui Amy Liu; Ola Abu Al Karsaneh; Shirin Soleimani; Hagay Ladany; David Chen; Matthew Zatzman; Vanja Cabric; Liana Nobre; Vanessa Bianchi; Melissa Edwards; Lauren C Sambira Nahum; Ayse B Ercan; Arash Nabbi; Shlomi Constantini; Rina Dvir; Michal Yalon-Oren; Gadi Abebe Campino; Shani Caspi; Valerie Larouche; Alyssa Reddy; Michael Osborn; Gary Mason; Scott Lindhorst; Annika Bronsema; Vanan Magimairajan; Enrico Opocher; Rebecca Loret De Mola; Magnus Sabel; Charlotta Frojd; David Sumerauer; David Samuel; Kristina Cole; Stefano Chiaravalli; Maura Massimino; Patrick Tomboc; David S Ziegler; Ben George; An Van Damme; Nobuko Hijiya; David Gass; Rose B McGee; Oz Mordechai; Daniel C Bowers; Theodore W Laetsch; Alexander Lossos; Deborah T Blumenthal; Tomasz Sarosiek; Lee Yi Yen; Jeffrey Knipstein; Anne Bendel; Lindsey M Hoffman; Sandra Luna-Fineman; Stefanie Zimmermann; Isabelle Scheers; Kim E Nichols; Michal Zapotocky; Jordan R Hansford; John M Maris; Peter Dirks; Michael D Taylor; Abhaya V Kulkarni; Manohar Shroff; Derek S Tsang; Anita Villani; Wei Xu; Melyssa Aronson; Carol Durno; Adam Shlien; David Malkin; Gad Getz; Yosef E Maruvka; Pamela S Ohashi; Cynthia Hawkins; Trevor J Pugh; Eric Bouffet; Uri Tabori
Journal:  Nat Med       Date:  2022-01-06       Impact factor: 87.241

Review 3.  Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review.

Authors:  Xiaojun Liu; Liang Qiao
Journal:  Front Nutr       Date:  2022-03-25

Review 4.  Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?

Authors:  Mo-Xuan Wang; Shu-Yue Gao; Fan Yang; Run-Jia Fan; Qin-Na Yang; Tian-Lan Zhang; Nian-Song Qian; Guang-Hai Dai
Journal:  World J Clin Oncol       Date:  2022-09-24

5.  Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.

Authors:  Shiyu Mao; Junfeng Zhang; Yadong Guo; Ziwei Zhang; Yuan Wu; Wentao Zhang; Longsheng Wang; Jiang Geng; Yang Yan; Xudong Yao
Journal:  Drug Des Devel Ther       Date:  2019-01-11       Impact factor: 4.162

6.  The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.

Authors:  Wenxiao Jia; Qianqian Gao; Anqin Han; Hui Zhu; Jinming Yu
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248

7.  Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report.

Authors:  Ning Yang; Pin-Liang Zhang; Zeng-Jun Liu
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.